Since the majority of breast cancer patients are ER+, our finding that SERPINA1 can predict survival in ER+ patients suggests that it could be a potential prognostic marker, and many patients may benefit from this additional knowledge. The gene discussed is SERPINA1; the disease is breast carcinoma.